PROFESSIONAL EDITION

The largest community of pharma leaders

Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®

CANTON, Mass.–()–Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform.

“We have worked with the Trianni Mouse across several therapeutic antibody programs and have been impressed with the success of these campaigns,” commented Colby Souders, Ph.D., Chief Scientific Officer of Abveris. “Abveris is uniquely positioned to dramatically shorten therapeutic discovery timelines while enhancing candidate selection by pairing optimized immunization methods in the Trianni Mouse with high-resolution single B cell screening enabled by the Berkeley Lights Beacon.”

“We believe this partnership brings together powerful discovery technologies with the potential for accelerating Nkarta’s pipeline of natural killer cell therapy candidates,” said James Trager, Ph.D., Chief Scientific Officer of Nkarta. “We look forward to working closely with the Abveris team on the identification of targeted antibodies ideally suited for our cell engineering and manufacturing platform.”

“The Nkarta team is situated to redefine the way we think about cell therapies, and we are delighted to be working with their team of impassioned scientists,” added Tracey Mullen, MBA, Chief Operating Officer of Abveris. “This partnership highlights our continued commitment to working with organizations leveraging antibody therapeutics in innovative and transformative ways.”

“We at Trianni are thrilled that the partnership of Abveris and Nkarta includes the use of the Trianni Mice. It is gratifying to contribute to the program of creating novel antibody therapeutics,” said Matthias Wabl, Ph.D., Chief Executive Officer of Trianni, Inc.

About Abveris:

Abveris is Boston’s premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Trianni, Inc.

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. Trianni’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. Trianni’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about Trianni is available through its corporate website, www.TRIANNI.com.

Source

Recent Articles